GLP-1 drugs comparison

Endocrinology

Compare GLP-1 receptor agonists for type 2 diabetes and weight management. These drugs have become some of the most prescribed (and most denied) medications in the U.S. Coverage varies dramatically between diabetes and weight loss indications.

Select any two to compare side by side

All products in this comparison

ProductManufacturerRouteFrequencyKey difference
OzempicNovo NordiskSC injectionWeeklyMost prescribed GLP-1 for T2D; semaglutide; cardiovascular benefit data
WegovyNovo NordiskSC injectionWeeklyHigher-dose semaglutide for chronic weight management; FDA-approved for obesity
MounjaroEli LillySC injectionWeeklyDual GIP/GLP-1 agonist (tirzepatide); superior A1C and weight reduction
ZepboundEli LillySC injectionWeeklyTirzepatide for chronic weight management; FDA-approved for obesity
RybelsusNovo NordiskOral (tablet)DailyOnly oral GLP-1; taken on empty stomach; semaglutide

Related guides

Denied one of these medications?

Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.